Table 1.

Effect of KB-R7785 on GVHD-Associated Lymphoid Hypoplasia

MiceCell No. (×107)
H-2Kd+Kb+H-2Kd−Kb+
CD4+CD8+B220+CD4+CD8+B220+
Normal 2.4 ± 0.7 1.3 ± 0.1 7.0 ± 0.1  —   —   —  
GVHD 1.1 ± 0.1 1.0 ± 0.1 1.4 ± 0.5 1.1 ± 0.5 1.0 ± 0.1 0.5 ± 0.2 
KB-R7785 4.4 ± 1.3 4.2 ± 1.0 7.3 ± 1.4 3.8 ± 0.6 4.8 ± 1.3 6.0 ± 1.2 
MiceCell No. (×107)
H-2Kd+Kb+H-2Kd−Kb+
CD4+CD8+B220+CD4+CD8+B220+
Normal 2.4 ± 0.7 1.3 ± 0.1 7.0 ± 0.1  —   —   —  
GVHD 1.1 ± 0.1 1.0 ± 0.1 1.4 ± 0.5 1.1 ± 0.5 1.0 ± 0.1 0.5 ± 0.2 
KB-R7785 4.4 ± 1.3 4.2 ± 1.0 7.3 ± 1.4 3.8 ± 0.6 4.8 ± 1.3 6.0 ± 1.2 

Cell numbers of CD4+ T, CD8+ T, and B220+ B cells of host (H-2Kd+Kb+) or donor (H-2Kd−Kb+) origin in splenocytes from normal CBF1, GVHD, or KB-R7785–treated mice on day 14 were calculated from the total numbers of splenocytes recovered and the percentages of each subpopulation were determined by three-color flow cytometric analysis. Data represent the mean ± SD of 3 mice in each group.

Close Modal

or Create an Account

Close Modal
Close Modal